Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Dopamine Receptor
    (1)
  • Histamine Receptor
    (2)
  • OX Receptor
    (3)
  • Others
    (3)
Filter
Search Result
Results for "

narcolepsy

" in TargetMol Product Catalog
  • Inhibitor Products
    9
    TargetMol | Activity
Pitolisant
T60636362665-56-3
Pitolisant (Tiprolisant) is a selective and potent non-imidazole recombinant human histamine H3 receptor antagonist for the study of excessive daytime sleepiness and sudden collapse in patients with episodic narcolepsy.
  • $40
In Stock
Size
QTY
Samelisant
T97701394808-82-2
Samelisant (SUVN-G3031) is a selective and inverse agonist of H3 receptor with Kis of 8.7 nM and 9.8 nM for human and rat. Samelisant has anticataplectic effects and can be used in studies about narcolepsy.
  • $113
In Stock
Size
QTY
Almorexant
T2613871224-64-5
Almorexant (ACT 078573) is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM for OX1 and OX2, respectively.
  • $39
In Stock
Size
QTY
YNT-185
T392291804978-81-1
YNT-185 is a nonpeptide, selective agonist of the orexin type-2 receptor (OX2R), demonstrating EC50 values of 0.028 μM and 2.75 μM for OX2R and OX1R, respectively. Furthermore, YNT-185 effectively alleviates symptoms of narcolepsy-cataplexy in mouse models.
  • $60
In Stock
Size
QTY
Firazorexton hydrate
T786362861934-86-1
Firazorexton hydrate (TAK-994) is a brain-penetrant and orally active agonist of the orexin type 2 receptor (OX2R) with a potent EC50 of 19 nM. It effectively reduces wakefulness fragmentation and cataplexy-like episodes in mouse models of narcolepsy [1].
  • Inquiry Price
Size
QTY
GSK 189254 HCl
T19628945493-87-8
GSK 189254A is a histamine H3 receptor antagonist for the treatment of narcolepsy. Histamine H3 receptor antagonists have been shown to increase the release of neurotransmitters in the brain and to enhance cognition in vivo. The compound may also be usefu
  • $1,520
6-8 weeks
Size
QTY
BisfluoroModafinil
T426290280-13-0
CRL-40940 is a selective dopaminergic reuptake inhibitor
  • $40
In Stock
Size
QTY
YNT-185 dihydrochloride
T371121804978-82-2
Potent and selective orexin OX2 receptor agonist (EC50 = 28 nM at human OX2 expressed in CHO cells). Displays approximately 100-fold selectivity for OX2 over OX1 (EC50 = 2.75 μM at human OX1 expressed in CHO cells). Depolarizes OX2-expressing histaminergic neurons in mouse brain slices. Increases wake time in wild type mice. Suppresses cataplexy-like symptoms in OX knockout mice. Nagahara et al (2015) Design and synthesis of non-peptide, selective orexin receptor 2 agonists. J.Med.Chem. 58 7931 PMID:26267383 |Irukayama-Tomobe et al (2017) Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc.Natl.Acad.Sci.USA. 144 5731 PMID:28507129
  • $113
5 days
Size
QTY
Almorexant hydrochloride
T6155913358-93-7
Almorexant hydrochloride (ACT-078573 hydrochloride) is a potent and competitive dual orexin 1 receptor (OX1) orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM for OX1 and OX2, respectively.
  • $70
7-10 days
Size
QTY